Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
NICE Pembrolizumab Recommendation for Locally Advanced Head and Neck Cancer Treatment
NICE Pembrolizumab recommendation offers a major advance for adults with resectable locally advanced head and neck squamous cell carcinoma. This update provides an evidence-based overview of the final draft guidance issued by NICE recommending pembrolizumab, within its marketing authorisation, fo...
PEPFAR TB Impact: Averting Millions of Cases and Deaths Among HIV Patients
PEPFAR TB Impact has been profound, with the U.S. President’s Emergency Plan for AIDS Relief averting an estimated 11.0 million tuberculosis (TB) cases and 2.1 million TB-related deaths among persons with HIV between 2003 and 2024. The PEPFAR TB impact extends far beyond HIV, delivering substa...
Vitamin B6 Depletion Risk in Carbidopa/Levodopa Therapy and Seizure Implications
Carbidopa/levodopa products used for Parkinson’s disease can cause vitamin B6 depletion risk, potentially leading to seizures. The U.S. Food and Drug Administration (FDA) has identified 14 cases of seizures linked to vitamin B6 deficiency, all occurring in patients taking levodopa doses above 1,0...